Incidence of adverse and safety events in individuals with Parkinson’s disease treated with catechol-o-methyltransferase inhibitor opicapone as an add-on to levodopa treatment: a systematic review and meta-analysis. (2025). Prospects in Pharmaceutical Sciences, 23(4), 175-185. https://doi.org/10.56782/pps.563